Jade Biosciences, Inc. - Common Stock, $0.0001 par value (JBIO) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2025 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value
Symbol
JBIO on Nasdaq
Shares outstanding
51,675,374
Price per share
$15.64
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
47,075,378
Total reported value
$726,260,386
% of total 13F portfolios
0%
Share change
+13,832,194
Value change
+$242,240,917
Number of holders
102
Price from insider filings
$15.64
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Jade Biosciences, Inc. - Common Stock, $0.0001 par value (JBIO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Fairmount Funds Management LLC 20% 0% $89,373,614 +$26,797,898 10,353,875 +43% Fairmount Funds Management LLC 06 Oct 2025
Venrock Healthcare Capital Partners III, L.P. 9.9% 0% $70,905,847 +$26,271,533 5,115,862 +59% Venrock Healthcare Capital Partners III, L.P. 31 Dec 2025
FMR LLC 15% $40,965,976 4,735,951 FMR LLC 30 May 2025
Bellevue Group AG 6.8% $46,307,688 3,341,103 Bellevue Group AG 16 Dec 2025
RA CAPITAL MANAGEMENT, L.P. 7% +72% $27,758,364 +$16,318,579 3,214,969 +143% RA Capital Management, L.P. 08 Oct 2025
JANUS HENDERSON GROUP PLC 6.2% $42,459,514 3,063,457 JANUS HENDERSON GROUP PLC 31 Dec 2025
BlackRock, Inc. 6.6% +26% $18,565,068 +$3,763,302 2,150,203 +25% BlackRock, Inc. 30 Sep 2025
VANGUARD GROUP INC 4.2% -23% $32,337,685 +$4,446,695 2,095,767 +16% The Vanguard Group 31 Dec 2025
Frazier Life Sciences Public Fund, L.P. 4.2% 0% $11,949,495 +$379,228 1,384,646 +3.3% Frazier Life Sciences Public Fund, L.P. 30 Sep 2025
TCG Crossover GP I, LLC 0.2% $649,193 64,023 TCG Crossover GP I, LLC 28 Apr 2025
Atlas Venture Fund XII, L.P. 0.2% $521,257 51,406 Atlas Venture Associates XII, L.P. 28 Apr 2025

As of 31 Dec 2025, 102 institutional investors reported holding 47,075,378 shares of Jade Biosciences, Inc. - Common Stock, $0.0001 par value (JBIO). This represents 91% of the company’s total 51,675,374 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Jade Biosciences, Inc. - Common Stock, $0.0001 par value (JBIO) together control 84% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 13% 6,894,488 +41% 0.01% $106,381,950
Fairmount Funds Management LLC 8.8% 4,553,494 +41% 5.3% $70,260,412
RA CAPITAL MANAGEMENT, L.P. 7.1% 3,671,083 +246% 0.58% $56,644,811
Bellevue Group AG 6.5% 3,341,103 0.98% $51,553,219
VR ADVISER, LLC 6.2% 3,220,364 0% 2.5% $49,690,217
BlackRock, Inc. 5.6% 2,870,313 +33% 0% $44,288,930
VANGUARD GROUP INC 4.1% 2,095,767 +21% 0% $32,337,685
BAKER BROS. ADVISORS LP 3.2% 1,641,137 0.15% $25,322,744
Remedium Capital Partners, LLC 3.1% 1,577,750 0% 14% $24,345,000
Versant Venture Management, LLC 3% 1,525,820 0% 16% $23,543,403
RTW INVESTMENTS, LP 2.8% 1,449,273 0% 0.22% $22,362,282
Avidity Partners Management LP 2.7% 1,400,708 +24% 6.2% $21,612,924
SAMSARA BIOCAPITAL, LLC 1.9% 968,798 +82% 1.5% $14,948,553
Driehaus Capital Management LLC 1.7% 887,179 -29% 0.09% $13,689,172
MARSHALL WACE, LLP 1.7% 875,273 +2199% 0.01% $13,505,462
Aberdeen Group plc 1.7% 867,284 0.02% $13,382,192
GEODE CAPITAL MANAGEMENT, LLC 1.6% 841,808 +26% 0% $12,991,338
GREAT POINT PARTNERS LLC 1.6% 806,273 +27% 4% $12,440,792
Soleus Capital Management, L.P. 1.5% 796,744 0% 0.52% $12,293,760
Affinity Asset Advisors, LLC 1.4% 714,956 +995% 0.79% $11,031,771
STATE STREET CORP 1.2% 642,921 +29% 0% $9,920,271
Point72 Asset Management, L.P. 1.1% 558,474 0.01% $8,617,254
ORBIMED ADVISORS LLC 1% 531,163 0% 0.18% $8,195,845
Opaleye Management Inc. 0.83% 427,608 0.88% $6,597,991
Logos Global Management LP 0.76% 395,000 -37% 0.41% $6,094,850

Institutional Holders of Jade Biosciences, Inc. - Common Stock, $0.0001 par value (JBIO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 47,075,378 $726,260,386 +$242,240,917 $15.43 102
2025 Q3 31,617,300 $272,859,518 +$407,366 $8.63 74
2025 Q2 31,531,484 $315,000,764 +$314,968,047 $9.99 70